Manufacturing standards are considered key to preventing drug recalls and shortages.

被引：0
|
作者：
Wechsler, Jill
机构：
来源：
BIOPHARM INTERNATIONAL | 2013年 / 26卷 / 10期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：12 / 13
页数：2
相关论文
共 31 条
  • [21] Custom manufacturing - cGMP problems slow key drug introductions
    Schmitt, B
    Morrison, S
    CHEMICAL WEEK, 2001, 163 (37) : 23 - 24
  • [22] Optimization of key energy and performance metrics for drug product manufacturing
    Chen, Yingjie
    Kotamarthy, Lalith
    Dan, Ashley
    Sampat, Chaitanya
    Bhalode, Pooja
    Singh, Ravendra
    Glasser, Benjamin J.
    Ramachandran, Rohit
    Ierapetritou, Marianthi
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2023, 631
  • [23] Modern drug manufacturing key to covid-19 response
    Wechsler, Jill
    Pharmaceutical Technology, 2020, 44 (05) : 14 - 15
  • [24] Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries
    Bochenek, Tomasz
    Abilova, Vafa
    Alkan, Ali
    Asanin, Bogdan
    de Miguel Beriain, Inigo
    Besovic, Zeljka
    Bonanno, Patricia Vella
    Bucsics, Anna
    Davidescu, Michal
    De Weerdt, Elfi
    Duborija-Kovacevic, Natasa
    Furst, Jurij
    Gaga, Mina
    Gailite, Elma
    Gulbinovic, Jolanta
    Gurpinar, Emre U.
    Hanko, Balazs
    Hargaden, Vincent
    Hotvedt, Tor A.
    Hoxha, Iris
    Huys, Isabelle
    Inotai, Andras
    Jakupi, Arianit
    Jenzer, Helena
    Joppi, Roberta
    Laius, Ott
    Lenormand, Marie-Camille
    Makridaki, Despina
    Malaj, Admir
    Margus, Kertu
    Markovic-Pekovic, Vanda
    Miljkovic, Nenad
    de Miranda, Joao L.
    Primozic, Stanislav
    Rajinac, Dragana
    Schwartz, David G.
    Sebesta, Robin
    Simoens, Steven
    Slaby, Juraj
    Sovic-Brkicic, Ljiljana
    Tesar, Tomas
    Tzimis, Leonidas
    Warminska, Ewa
    Godman, Brian
    FRONTIERS IN PHARMACOLOGY, 2018, 8
  • [25] The strategic relevance of manufacturing technology: An overall quality concept to promote innovation preventing drug shortage
    Panzitta, Michele
    Ponti, Mauro
    Bruno, Giorgio
    Cois, Giancarlo
    D'Arpino, Alessandro
    Minghetti, Paola
    Mendicino, Francesca Romana
    Perioli, Luana
    Ricci, Maurizio
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 516 (1-2) : 144 - 157
  • [26] Chemotherapy administration safety standards for preventing medication errors and adverse drug reactions in patients with breast cancers
    Pakdel, A. Fani
    Mousavi, M.
    Roohani, M. S.
    Elyasi, S.
    Kooshyar, M. M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] Supercoiled DNA percentage: A key in-process control of linear DNA template for mRNA drug substance manufacturing
    Piao, Xijun
    Tang, Yujie
    Li, Xiuzhi
    Zhang, Weicheng
    Yang, Wei
    Xu, Xining
    Wang, Wenjing
    Jiang, Jiajia
    Xu, Jun
    Hu, Kunkun
    Xu, Meiling
    Liu, Mengjie
    Sun, Mengfei
    Jin, Lin
    MOLECULAR THERAPY NUCLEIC ACIDS, 2024, 35 (02):
  • [28] Technoeconomic evaluation of separation solvents and technologies for Continuous Pharmaceutical Manufacturing (CPM) of four key Drug Substances (DS)
    Diab, Samir
    Gerogiorgis, Dimitrios I.
    CHIMICA OGGI-CHEMISTRY TODAY, 2018, 36 (03) : 16 - 19
  • [29] Manufacturing Standards Key to Advancing Cellular and Gene Therapies FDA works with industry on strategies for assuring high-quality regenerative medicines
    Wechsler, Jill
    BIOPHARM INTERNATIONAL, 2017, 30 (09) : 8 - 9
  • [30] Finding key impurities in different manufacturing routes of a drug substance using liquid chromatography/mass spectrometry followed by principal components analysis
    Carrier, Dan
    Eckers, Christine
    Arnoult, Tiffanie
    Thurston, Thomas
    Major, Hilary
    RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2007, 21 (23) : 3946 - 3948
1234